Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome
This medical study is looking into a new medicine called Vonafexor for individuals diagnosed with Alport Syndrome. Alport Syndrome is a genetic condition that mainly affects the kidneys, potentially leading to kidney disease over time. The main goal of this particular study, known as a Phase II trial, is to find out if Vonafexor is safe to use and to get an early idea of whether it might be effective in preventing the condition from getting worse. Researchers will carefully track any side effects that might occur while people are taking the medicine and for a short time afterwards. They will also be closely monitoring various health indicators, including kidney function, to see how the medicine affects the body. This helps doctors understand more about Vonafexor and if it could be a helpful treatment in the future.
At a glance
What is this study about?
This study is about a new medicine called Vonafexor, and it's for people who have Alport Syndrome. Alport Syndrome is a condition that can affect your kidneys, eyes, and ears, but it's kidney problems that are often the most serious. In this study, doctors are particularly interested in people whose Alport Syndrome is at risk of getting worse.
The main purpose of this study, often called a 'Phase II' trial, is to see two important things. Firstly, they want to make sure the medicine is safe. Are there any side effects, and how common are they? Secondly, they want to get an early idea if Vonafexor could help to stop or slow down the progression of Alport Syndrome. This means they are exploring if it has a positive effect on the condition.
To find this out, participants will take Vonafexor, and medical teams will closely watch their health. They'll check for any changes in their body, take blood tests, and monitor their overall well-being throughout the treatment period and for a couple of weeks afterwards. This careful monitoring helps researchers understand how the medicine behaves in the body and its potential benefits and risks. Studies like this are a really important step in developing new treatments for conditions like Alport Syndrome.
Key takeaways
- This study is testing a new medicine called Vonafexor for Alport Syndrome.
- It aims to find out if Vonafexor is safe and if it helps slow down kidney disease.
- Participants will receive the new medicine in a supervised way.
- Regular health checks, blood tests, and physical exams will be part of the study.
- The study includes a follow-up period after you stop taking the medicine.
Who may be eligible?
To be considered for this study, you need to be an adult, 18 years old or older. There isn't an upper age limit mentioned, so doctors will consider suitable adults of all ages.
This study is open to both men and women who have been diagnosed with Alport Syndrome and whose condition puts them at risk of it getting worse over time.
The research team will have other specific health requirements, and they will need to review your full medical history to confirm if taking part is safe and appropriate for you.
- Are you 18 years of age or older?
- Do you have a diagnosis of Alport Syndrome?
- Has your doctor told you your Alport Syndrome is at risk of getting worse?
- Are you comfortable attending regular clinic appointments?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you would be given the medicine called Vonafexor. The amount of medicine you receive might start at a lower dose and gradually increase over time, which is called a 'dose-escalation'. This allows the medical team to carefully observe how your body reacts to different amounts of the medicine.
During the study, you would have regular visits to the clinic. At these visits, doctors and nurses would perform physical examinations, check your vital signs like blood pressure and heart rate, and take blood and urine samples. These tests help them track your kidney function, monitor for any side effects, and understand how the medicine is working in your body.
After you finish taking the medicine, there will be follow-up appointments for about two weeks. This is to make sure your health is stable and to check for any delayed effects. The total length of your participation would depend on the study's design, including how long you take the medicine and the follow-up period. This would be clearly explained to you before you agree to join.
Potential risks and benefits
Locations (3)
- —Spain
- —France
- —Germany
Common questions
What is Alport Syndrome?
Alport Syndrome is a genetic kidney disease that can also affect hearing and vision. It causes damage to the tiny filtering units in the kidneys over time.
What is Vonafexor?
Vonafexor is a new medicine being tested to see if it can help people with Alport Syndrome and slow down its impact on the kidneys.
What does 'Phase II' mean?
A 'Phase II' study means it's an early stage of testing. Doctors are looking at safety and if the medicine has any positive effects, but it's not yet proven for general use.
Will I definitely get the new medicine?
Yes, in this study, the aim is to give participants Vonafexor to see its effects. Sometimes trials use a placebo, but this study focuses on the active medicine.
How long will I be in the study?
The study will involve taking the medicine and then being monitored for about two weeks after your last dose. The exact total length will be explained by the study team.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.